BCRX BIOCRYST PHARMACEUTICALS INC

8-K Current Report

Filed: February 26, 2026

Health Care

Biological Products, (No Diagnostic Substances)

BIOCRYST PHARMACEUTICALS INC (BCRX) 8-K current report filed with SEC EDGAR on February 26, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q4 and full year 2025 financial results announced Feb 26, 2026 — full figures in Exhibit 99.1 press release
• Filing also covers "recent corporate developments," suggesting potential pipeline or business updates beyond routine earnings

Item 7.01 · Regulation FD Disclosure

• Reg FD disclosure references Exhibit 99.1 — contains the material information investors should review directly
• Standard legal language limiting liability; actual substance in attached exhibit, not this item text

Get deeper insights on BIOCRYST PHARMACEUTICALS INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.